Korean J Dermatol.
2011 Apr;49(4):382-384.
Erlotinib (Tarceva(R)) Induced Hair Abnormalities
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Kyunghee University, Seoul, Korea. bellotte@hanmail.net
Abstract
- Erlotinib is a low-molecular-weight quinazoline derivative that inhibits the activation of epidermal growth factor receptor (EGFR) tyrosine kinase through competitive binding of the adenosine triphosphate binding domain of the receptor. Patients undergoing anti-EGFR therapy frequently present with cutaneous reactions like a sterile follicular and pustular rash, xerosis, pruritus, paronychia, hair abnormalities and mucositis, which can cause serious discomfort and negatively affect the compliance with anti-EGFR therapy. We report here on an interesting case of hair abnormalities induced by erlotinib (Tarceva(R)) and this presented as eyelash lengthening and hair curling in a 62-year-old woman.
MeSH Terms
-
Adenosine Triphosphate
Binding, Competitive
Compliance
Exanthema
Female
Hair
Humans
Middle Aged
Mucositis
Paronychia
Polyphosphates
Protein-Tyrosine Kinases
Pruritus
Quinazolines
Receptor, Epidermal Growth Factor
Erlotinib Hydrochloride
Adenosine Triphosphate
Polyphosphates
Protein-Tyrosine Kinases
Quinazolines
Receptor, Epidermal Growth Factor
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Acneiform Eruption Induced by Erlotinib (Tarceva(R))
- Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors
- Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis
- A Case of Acneiform Eruption and Paronychia Occurring after Use of Erlotinib (Tarceva(R))
- Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer
